Tumor Acidity and CD44 Dual Targeting Hyaluronic Acid-coated Gold Nanorods for Combined Chemo- and Photothermal Cancer Therapy
Overview
Affiliations
In this work, tumor acidity and CD44 dual targeting hyaluronic acid-coated gold nanorods (AuNRs) are investigated for combined chemo- and photothermal cancer therapy. Low molecular weight hyaluronic acid (LMWHA) is conjugated with pH-sensitive groups for pH-induced aggregation and lipoic acid for coating of AuNRs. By changing pH-sensitive groups with different pKa values, pH-sensitivity of modified LMWHA can be tuned. After coating modified LMWHA onto AuNRs, biocompatibility of the AuNRs is significantly improved. These LMWHA-coated AuNRs can gradually aggregate under slightly acidic conditions, making them favorable for accumulation at acidic tumor sites. Surface LMWHA allows the nanocomposites to be selectively uptaken by CD44-expressing cancer cells, and AuNRs endows the nanocomposites with excellent photothermal ability. Loading of doxorubicin, a chemical drug, provides the LMWHA-coated AuNRs synergistic cancer cell-killing (in vitro) and tumor growth inhibiting (in vivo) ability. Taken together, these results demonstrate that this multifunctional nanosystem with pH-induced aggregation and CD44 targeting has potential for combined chemo- and photothermal cancer therapy.
Yang C, Liao X, Zhou K, Yao Y, He X, Zhong W Bioact Mater. 2025; 48:1-17.
PMID: 40028237 PMC: 11870144. DOI: 10.1016/j.bioactmat.2025.02.014.
Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics.
Urbano-Gamez J, Guzzi C, Bernal M, Solivera J, Martinez-Zubiaurre I, Caro C Int J Mol Sci. 2024; 25(10).
PMID: 38791253 PMC: 11121233. DOI: 10.3390/ijms25105213.
Gold Nanomaterial System That Enables Dual Photothermal and Chemotherapy for Breast Cancer.
Wang L, Shrestha B, Brey E, Tang L Pharmaceutics. 2023; 15(9).
PMID: 37765168 PMC: 10534904. DOI: 10.3390/pharmaceutics15092198.
Uthappa U, Suneetha M, Ajeya K, Ji S Pharmaceutics. 2023; 15(6).
PMID: 37376161 PMC: 10302411. DOI: 10.3390/pharmaceutics15061713.
Yang B, Yin S, Zhou Z, Huang L, Xi M Cancers (Basel). 2023; 15(7).
PMID: 37046797 PMC: 10093113. DOI: 10.3390/cancers15072136.